Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Drug |
Pharmacologic Class |
Indication |
More Information |
| Allergic Disorders | |||
| Xolair (omalizumab) | Anti-immunoglobulin E (IgE) antibody | For the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to 1 or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy. | Xolair Approved for Adults and Pediatric Patients With IgE-Mediated Food Allergy |
| Dermatological Disorders | |||
| Aurlumyn (iloprost) | Prostacyclin mimetic | Treatment of severe frostbite in adults to reduce the risk of finger or toe amputation. | FDA Approves Aurlumyn for Treatment of Severe Frostbite |
| Gastrohepatic Disorders | |||
| Eohilia (budesonide oral suspension) | Corticosteroid | Treatment of adults and pediatric patients 11 years of age and older with eosinophilic esophagitis. | Eohilia, an Oral Therapy for Eosinophilic Esophagitis, Gets FDA Approval |
| Infectious Diseases | |||
| Exblifep (cefepime/enmetazobactam) | Cephalosporin antibacterial plus a beta-lactamase inhibitor | Treatment of patients 18 years of age and older with complicated urinary tract infections, including pyelonephritis. | Exblifep Approved for Complicated UTI, Including Pyelonephritis |
| Neurologic Disorders | |||
| Motpoly XR (lacosamide) | Anticonvulsant | Treatment of partial-onset seizures in adult and pediatric patients weighing at least 50kg. | Motpoly XR, a Once-Daily Formulation of Lacosamide, Now Available |
| Oncology | |||
| Amtagvi (lifileucel) |
Tumor-derived autologous T cell immunotherapy
|
Treatment of adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. | One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma |
| Onivyde (irinotecan liposome) |
Topoisomerase inhibitor
|
In combination with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. | Onivyde Regimen Approved as First-Line Tx for Metastatic Pancreatic Adenocarcinoma |
| Tagrisso (osimertinib) |
Kinase inhibitor
|
Treatment of adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. | Tagrisso Approved for First-Line Tx of EGFR Mutation Positive Advanced NSCLC |
| Tepmetko (tepotinib) |
Kinase inhibitor
|
Treatment of adults with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 (MET ex14) skipping alterations. | Tepmetko Gets Traditional Approval for MET Exon 14-Skipping NSCLC |
Please login or register first to view this content.
